Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of the Safety, Tolerability, Feasibility and Efficacy of Anti-PD-1 or Anti-PD-L1 in Combination With a Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)

NCT03715985 is registered in ClinicalTrials.gov with Herlev Hospital as lead sponsor.

NCT NCT03715985
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03715985 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of the Safety, Tolerability, Feasibility and Efficacy of Anti-PD-1 or Anti-PD-L1 in Combination With a Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)
Lead sponsor
Herlev Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
January 28, 2019
Completion date
December 1, 2022
Enrollment
12 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

bladder urothelial carcinoma, metastatic, malignant melanoma, metastatic, non small cell lung cancer metastatic